Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy on neurological diseases market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Growth Outlook For The Gene Therapy On Neurological Diseases Market?

The market size for gene therapy on neurological diseases has experienced significant growth in recent years. It is anticipated to expand from $3.13 billion in 2024 to $3.55 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.2%. This historical expansion can be attributed to several factors, including the increasing prevalence of neurological disorders, rising demand for personalized medicine, growing investment in biotech research and development, increasing clinical trial activities, and rising approvals for gene therapies.

The gene therapy on neurological diseases market size is anticipated to see considerable expansion in the upcoming years. This market is set to reach $5.76 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 12.9%. The projected growth for this period can be attributed to an increase in global clinical trial activity, ongoing development of healthcare infrastructure, rising awareness of rare diseases, an expanding pipeline of gene therapies, and a growth in partnerships and collaborations. Significant trends during the forecast period encompass the integration of technology in remote patient monitoring, innovations in vector manufacturing platforms, automation in biomanufacturing driven by technology, the development of gene therapies for ultra-rare pediatric central nervous system (CNS) disorders, and the incorporation of genomic screening into clinical settings.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

What Growth-Enabling Forces Are Impacting The Gene Therapy On Neurological Diseases Market?

The rising occurrence of neurological conditions is anticipated to fuel the expansion of the gene therapy on neurological diseases market in the foreseeable future. These conditions are health issues impacting the brain, spinal cord, and nerves, resulting in various symptoms such as cognitive, motor, and sensory difficulties. The growing incidence of neurological disorders is connected to an aging demographic, given that aging progressively hinders neuronal function, diminishes brain plasticity, and heightens oxidative stress, thereby facilitating the onset and advancement of these conditions. Gene therapy on neurological diseases assists in managing neurological disorders by addressing their underlying genetic causes, presenting prospects for enduring or permanent treatment options. This therapy enhances patient results through the restoration or modification of gene function, alleviating symptoms, and decreasing the necessity for repeated interventions, consequently improving the overall quality of life. For example, in July 2024, data from the National Health Service, a UK-based government agency, indicated that 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, which marked an increase of 3,155 cases relative to May 31, 2024. Consequently, the rising prevalence of neurological disorders is stimulating the growth of the gene therapy on neurological diseases market.

How Does The Gene Therapy On Neurological Diseases Market Differ By Segment?

The gene therapy on neurological diseases market covered in this report is segmented

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What New Opportunities Are Emerging From Trends In The Gene Therapy On Neurological Diseases Market?

Leading companies in the gene therapy on neurological diseases market are prioritizing the development of advanced viral delivery systems, like the adeno-associated virus serotype 2 (AAV2) vector, to improve targeted gene delivery, increase efficacy, lessen immune reactions, and enable long-term treatments. The adeno-associated virus serotype 2 (AAV2) vector is a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into target cells, particularly neurons, for prolonged expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for a gene therapy designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy utilizes an AAV2 vector to introduce a functional copy of the DDC gene into the putamen, thereby enabling dopamine production and enhancing motor functions. It features a single, intraputaminal infusion intended to deliver sustained therapeutic benefits, significantly improving motor function and reducing debilitating symptoms without requiring repeated interventions.

Who Are The Most Influential Companies In The Gene Therapy On Neurological Diseases Market?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

Which Region Is Leading Innovation In The Gene Therapy On Neurological Diseases Market?

North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2025, By The Business Research Company

Switchboard Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Surfing Boards Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Mobile Gaming Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mobile-gaming-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model